What does the NextGen GeneCore Immunotherapy Panel at Metropolis Healthcare include?
It measures Tumor Mutational Burden, MSI status, and PD-L1 expression (22C3) to guide immunotherapy selection.
How does Metropolis Healthcare perform this advanced immunotherapy panel?
Metropolis Healthcare uses high-coverage NGS for TMB/MSI evaluation and validated IHC methods for PD-L1 22C3 scoring.
Who should consider taking this immunotherapy panel at Metropolis Healthcare?
Patients with solid tumors who are being assessed for immune checkpoint inhibitor eligibility should take this test.
Is fasting required for this test at Metropolis Healthcare?
No fasting is required; the test uses tumor tissue and/or blood depending on clinical needs.
How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to detailed sequencing and PD-L1 evaluation.
Can this test at Metropolis Healthcare help select immunotherapy treatment?
Yes, it identifies biomarkers that predict response to PD-1/PD-L1 inhibitors and other immunotherapies.
How accurate is this panel at Metropolis Healthcare?
Metropolis Healthcare ensures high accuracy with deep sequencing, validated PD-L1 22C3 assays, and strict quality protocols.
Can this panel help in prognosis and therapy planning at Metropolis Healthcare?
Yes, the combined TMB, MSI, and PD-L1 data support personalized treatment decisions and long-term therapeutic strategies.